Advicenne S.A. (EPA: ALDVI)

Market Cap	26.35M
Revenue (ttm)	3.33M
Net Income (ttm)	-8.83M
Shares Out	12.28M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,919
Open	2.120
Previous Close	2.110
Day's Range	2.090 - 2.120
52-Week Range	0.827 - 3.080
Beta	1.52
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 19, 2024

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 21
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2023, Advicenne's revenue was 3.27 million, an increase of 10.98% compared to the previous year's 2.94 million. Losses were -7.03 million, -38.70% less than in 2022.